Welcome to our dedicated page for DAXOR SEC filings (Ticker: DXR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Daxor Corporation (NASDAQ: DXR) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as a public issuer. Daxor is a medical instrumentation and biotechnology company focused on blood volume measurement, and its filings offer detail on corporate events, governance and the development of its Blood Volume Analysis (BVA) technology.
Through current reports such as Form 8-K, Daxor discloses material events, including FDA 510(k) clearance for its next-generation rapid, portable, lab-based Blood Volume Analyzer (Daxor BVA™) and outcomes of shareholder meetings, such as director elections and auditor ratification. These documents also restate the company’s description as a developer and marketer of the BVA-100 Blood Volume Analyzer, the first FDA-cleared diagnostic blood test to objectively quantify blood volume status and composition compared to patient-specific norms.
On Stock Titan, users can review Daxor’s SEC filings alongside AI-powered summaries that explain the significance of each document in clear language. This includes annual and quarterly reports when filed (Forms 10-K and 10-Q), which typically discuss the company’s business, risk factors and financial condition, as well as Form 4 and related insider transaction reports when available, which detail trades by directors and officers.
Real-time updates from the SEC’s EDGAR system help ensure that new DXR filings are quickly reflected. The AI tools on the platform can highlight key points in lengthy filings, such as descriptions of the BVA product line, regulatory milestones, and information about the company’s Nasdaq listing and corporate structure. This makes it easier for investors and researchers to understand how Daxor’s regulatory disclosures relate to its blood volume analysis business.
Daxor Corporation reported a transformative 2025 as it shifts from an investment fund profile toward operating-company reporting. Net assets increased to $45,887,266 and Net Asset Value rose to $9.07 per share at December 31, 2025. The operating division was valued at $46,000,000 and generated unaudited revenue growth of 45% year-over-year while recording an operating loss of $268,598 for 2025, improved from a $1,614,545 loss in 2024. Daxor received FDA 510(k) clearance in August 2025 for its next-generation portable Blood Volume Analyzer, reported accelerating clinical validation and new hospital adoptions, and sold its remaining investment-portfolio positions in December 2025. Subsequent to year-end, Daxor completed a registered direct offering in January 2026 raising approximately $9.0 million at $11.75 per share. The company filed to change its primary reporting framework from the Investment Company Act to the Securities Exchange Act to align reporting with its operating focus.
Daxor Corporation entered into a definitive securities purchase agreement on January 23, 2026, to raise capital through a registered direct offering. The company issued and sold an aggregate of 765,958 registered shares of common stock at $11.75 per share, resulting in approximately $8,142,006 in net proceeds after placement agent fees and expenses. The closing occurred on January 26, 2026.
The common shares were issued under Daxor’s shelf registration statement on Form N-2 (File No. 333-281622), which was declared effective by the SEC on January 20, 2026. Lake Street Capital Markets, LLC acted as placement agent under a placement agency agreement executed the same day as the securities purchase agreement. The company also filed a legal opinion from Foley & Lardner LLP regarding the validity of the common stock.
Daxor Corporation is conducting a registered direct offering of 765,958 shares of common stock at $11.75 per share, for a stated gross offering size of $9,000,006. After paying an 8.0% placement fee to Lake Street Capital Markets and estimated offering expenses, Daxor expects net proceeds of about $8.14 million.
The company plans to use the cash for working capital and general corporate purposes, including product development, capital expenditures, potential investments or acquisitions, and repayment of some outstanding borrowings, with any unused funds temporarily invested in investment‑grade preferred stocks. As of January 22, 2026, Daxor had 5,061,267 common shares outstanding, a market price of $13.70 per share, and a net asset value of $6.98 per share, meaning the stock traded at a substantial premium to NAV. Daxor is registered as a closed‑end investment company but intends to seek an order under Section 8(f) of the Investment Company Act to cease being a registered investment company, which would remove Investment Company Act protections if granted.
Daxor Corporation, a Nasdaq-listed medical instrumentation and biotechnology company that is registered as a closed-end investment company, plans a registered direct offering of common stock to institutional investors through Lake Street Capital Markets as placement agent. The company notes that, under SEC rules for smaller issuers, the aggregate market value of securities it may offer in any 12‑month period under this shelf is limited to one third of its public float, and cites a current capacity figure based on recent trading prices. Daxor intends to use net proceeds for working capital and general corporate purposes, including product development, capital expenditures, potential investments or acquisitions, and repayment of borrowings, with interim investment in investment‑grade preferred stocks. The company also states that it plans to apply under Section 8(f) of the Investment Company Act for an order declaring it has ceased to be a registered investment company, which would remove Investment Company Act protections if granted, while its shares remain listed on Nasdaq under the symbol DXR.
Daxor Corporation filed a current report to share its latest investor presentation with the market. The company used an 8-K under the "Other Events" section to formally furnish this material.
The filing states that the current investor presentation is attached as Exhibit 99.1, making it part of the public record. Daxor’s common stock, with a par value of $0.01 per share, trades on Nasdaq under the symbol DXR.
Daxor Corporation has filed a base prospectus to offer up to $25,000,000 of its common stock from time to time and to register shares for resale by the Joseph Feldschuh Estate. The company may sell shares directly, through agents or underwriters, with specific terms and pricing to be detailed in future prospectus supplements. Net proceeds from primary sales are expected to support working capital, product development, capital expenditures, potential investments or acquisitions, and debt repayment, with unused funds invested in investment-grade preferred securities.
The prospectus also registers common stock held by the Joseph Feldschuh Estate, which controls more than 50% of Daxor’s voting power; all proceeds from those resales will go to the selling shareholder, not the company. Daxor operates its BVA-100 blood volume analyzer and Volumex diagnostic kit from its Oak Ridge, Tennessee facility and relies heavily on an investment portfolio concentrated in electric utility stocks. The company intends to seek deregistration as a closed-end investment company, which would remove Investment Company Act protections for investors and could change its tax treatment; if that order is granted, offerings under this document would cease and be shifted to a different registration format.
Daxor Corp reported an insider equity transaction by its Chief Financial Officer, Robert J. Michel. On December 9, 2025, he acquired 3,000 shares of Daxor common stock at a stated price of $0, reflecting the vesting of a stock grant.
Following this transaction, the CFO beneficially owns 20,050 shares of Daxor common stock in direct ownership, according to the Form 4 disclosure.
Daxor Corp (DXR) reported an insider equity event by its Chief Medical Officer, John Jefferies. On November 12, 2025, he acquired 2,344 shares of Daxor common stock at a reported price of $0, coded as “P,” with the filing noting these shares were from a grant that vested on November 12, 2025.
Following this transaction, Jefferies beneficially owns 17,616 shares with direct ownership. The filing was made by one reporting person and identifies his role as Officer (Chief Medical Officer).
John Jefferies, Chief Medical Officer of DAXOR CORP (DXR), filed an Initial Statement of Beneficial Ownership reporting 15,272 shares of DAXOR common stock owned directly. The filing lists multiple stock options exercisable for a total of ≈18,181 underlying shares across various grant dates and strike prices, with several tranches vesting by 12/01/2025 and one option presently exercisable in full.